- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06055972
Impact of Patient-Centered Approach for Communicating Coronary Calcium on Cardiovascular Health
Study Overview
Status
Intervention / Treatment
Detailed Description
Objectives:
The overall goal of the proposed study is to improve cardiovascular health of smokers and previous smokers, as CAD is the most common cause of death in this population. Patients enrolled in lung cancer screening programs compose a highly suitable cohort of heavy smokers and previous smokers with 55-80 years of age for testing interventions that could improve the cardiovascular health of the population
The objective is to use coronary artery calcification burden, derived from computed tomography studies obtained for lung cancer screening purposes, to motivate patients into improving their health habits. The specific goal of this study is to test the efficacy of a patient-centered educational intervention based on CAC information in appropriate statin use and cardiovascular risk factor modification of a cohort of patients enrolled in lung cancer screening (LCS) programs across the country.
Recruitment:
Patients will be sent a mail or email research packet containing the invitation to join the study, the consent form and the baseline survey. Alternatively, patients could receive a phone call regarding information about the study
Consenting:
Following screening for eligibility, IRB-approved, HIPAA-compliant informed consent will be obtained by the Research Coordinators medical at the two participating institutions Patient registration can occur only after evaluation for eligibility is complete, eligibility criteria have been met, and the study site is approved by the ACR. Participants must have signed and dated all applicable informed consents and authorization forms.
Randomization:
Investigators will randomly select (coin flipping) first month as intervention yes/no and then alternate monthly until the end of the enrollment period. Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination.
Baseline Questionnaire:
After consent form is signed, patients will have the option to either complete research questionnaire independently or with the help of the research coordinator over a virtual visit Patient will then mail or email the survey back to the research coordinator.
Patient's demographics and socioeconomic status will be inquired including age, gender, gender-identity and race/ethnicity, level of education, range of income, and health insurance status. The baseline cardiovascular health questionnaire will include data on lifestyle and eating habits, smoking status, known cardiovascular diseases, previous cardiovascular interventions, known cardiovascular risk factors such as obesity, hypercholesterolemia, hypertension, family history of heart disease, current use of statins or aspirin, current recommendation to use Statins or aspirin, willingness to pursue lifestyle modifications to reduce cardiovascular risk, and co-morbidities.
An exercise activity level questionnaire (IPAQ-7), a standardized anxiety questionnaire (GAD-7) and a patient activation questionnaire (PAM short) will also be applied.
In addition to data obtained in the baseline questionnaire, medical records, when available, will be reviewed for confirmation of height, weight, and blood pressure at the time of lung cancer screening appointment.
6-Month Follow Up Questionnaire: Approximately 6 months after consent, patients will receive the follow up mail or email research packet containing the follow up questionnaire. Alternatively, patients can receive a follow-up phone call to review the questionnaire. Questionnaire will address the main study outcomes including changes in lifestyle like exercise habit (IPAQ-7), smoking cessation, weight loss, initiation or dose change of Statin or aspirin, adherence to statin or aspirin prescription, level of anxiety (GAD-7), activation level for health self-care (PAM-short), number of cardiovascular imaging tests (echocardiography, catheterization, cardiac stress test, cardiac CT or cardiac MR) performed, and number of clinical visits motivated by the intervention or not.
Image Analysis for Coronary Artery Calcium Quantification:
All patients will have received a Low Dose CT of the chest for Lung cancer screening, as part of their clinical care. The LCS CT images will be analyzed by the site chest radiologist as per clinical care, and the report will include a qualitative statement on burden of coronary artery calcifications (none, mild, moderate, or severe), based on current guideline recommendations. In patients randomized to the intervention arm, quantification of calcium score using the Agatston score method will be performed by a member of the research team and reviewed by study site PI.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michagan
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 50 to 80 years old
- More than 20 pack years of smoking
- Actively smoking or previous smokers who quit with the last 15 years
- Completed a Low-dose CT Scan for Lung Cancer Screening within 30 day of registration
Exclusion Criteria:
- Patients unable to understand the informed consent process
- Patients without a contact phone number or permanent address to receive the study intervention.
- Patients who do not understand the English language
- Patients with known CAD or prior heart surgery /intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Letter Recipients with Coronary Calcium Score/Educational Materials
Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination.
|
Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination which will include the following:
|
|
No Intervention: Non-Letter Recipients (Control)
Patients in the control group will not receive any letter in the mail with their coronary calcium score and educational materials.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Guideline-Appropriate High Cholesterol Care
Time Frame: 6 Months
|
Rate of statin use (how often patients are required to take statin medications) and adherence (how often patents comply with taking statin medications as prescribed) to prescription in patients with known hypercholesterolemia.
This will be determined by patients' self-reported answers to questions during interviews and review of medical records.
Both rate of statin use and patient compliance will be used to generate a single, overall assessment of how well patients are being treated for and managing their hypercholesteremia.
|
6 Months
|
|
Exercise Level
Time Frame: 6 Months
|
Changes in exercise level, surveyed using International Physical Activity Questionnaire (IPAQ-short) questionnaire.
The IPAQ-short questionnaire is comprised of 7, self-reported, open-ended questions surrounding individuals' last 7-day recall of physical activity.
The questionnaire estimates the total physical activity in Metabolic Equivalent of Task (METs)- min/week and time spent sitting.
Scores vary depending on the person's activity level throughout the preceding 7 days, and there is not defined range for scores, as the questions are open ended (e.g.
How many hours did you spend doing vigorous activities during the last 7days?).
|
6 Months
|
|
Patient Self-Reported Smoking Habits and Cessation
Time Frame: 6 Months
|
Patients' self-reported smoking habits will be assessed via phone call or questionnaire at baseline and 6-month follow-up.
|
6 Months
|
|
Weight loss
Time Frame: 6 Months
|
Patient reported weight changes
|
6 Months
|
|
Blood Pressure Control
Time Frame: 6 Months
|
Patient reported blood pressure changes and initiation of anti-hypertensive therapy.
Both systolic/diastolic blood pressure will be measured.
|
6 Months
|
|
Patient Anxiety
Time Frame: 6 Months
|
Patient anxiety, measured by changes in Generalize Anxiety Disorder-7 (GAD-7) anxiety questionnaire 6 months after intervention.
The GAD-7 questionnaire is rated on a scale from 0-21, with higher scores indicating higher patient self-reported anxiety levels.
|
6 Months
|
|
Number of Invasive/Noninvasive Hospitalizations
Time Frame: 6 Months
|
Clinical visits, cardiac imaging tests, and hospitalizations 6 months after the intervention, to be measured by medical record review (to be assessed by research coordinator at 6 month follow-up) and follow up phone survey (patient self-reporting).
Number of visits, obtained from both the patient interview and patient medical records, for both invasive and noninvasive hospitalizations, will be combined to generate a single number, or complete total number of visits patients have experienced 6 months after intervention.
|
6 Months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACR 4708
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk FactorsUnited States
-
Hull University Teaching Hospitals NHS TrustNot yet recruitingCardiovascular Surgery | Cardiovascular Diseases (CVD)United Kingdom
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS and other collaboratorsRecruitingCardiovascular Risk | Genetic Cardiovascular RiskItaly
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiovascular Diseases (CVD)United States
Clinical Trials on Educational Letter Post CT Examination
-
Northwestern UniversityAgency for Healthcare Research and Quality (AHRQ)TerminatedColorectal CancerUnited States
-
Swansea UniversityAbertawe Bro Morgannwg University Health BoardRecruitingPelvic Floor DysfunctionsUnited Kingdom
-
Maria Sklodowska-Curie National Research Institute...National Center for Research and Development, PolandUnknownColorectal Cancer | Patient Participation | ScreeningPoland
-
University of Alabama at BirminghamProcter and GambleCompleted
-
OsakidetzaCompleted
-
Case Comprehensive Cancer CenterTerminated
-
Baylor Research InstituteTerminatedConcussion, Mild Traumatic Brain InjuryUnited States
-
Seva FoundationQueen's University, Belfast; Indian Institute of Public Health, India; Seva Canada... and other collaboratorsCompletedDiabetic RetinopathyNepal
-
Sun Yat-sen UniversityRecruitingHepatocellular CarcinomaChina